Baxter International has announced the commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine).
Norepinephrine is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states. It works as a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
Baxter’s product is supplied in 250mL single-dose, ready-to-use containers with either 4mg (16mcg/mL) or 8mg (32mcg/mL) of norepinephrine. As the product is a ready-to-use formulation, no further dilution is required prior to infusion.
“Our ready-to-use formulation of norepinephrine allows hospitals to store this medication closer to patient care settings like the emergency department, intensive care unit and surgical areas, letting them administer it faster while reducing the risk of compounding errors or touch contamination,” said Heather Knight, general manager, US Hospital Products, Baxter.
- Baxter announces US. FDA approval and launch of ready-to-use cardiovascular medicine norepinephrine in premix formulation. News release. Baxter International Inc. Accessed September 23, 2021. https://www.businesswire.com/news/home/20210923005579/en/Baxter-Announces-U.S.-FDA-Approval-and-Launch-of-Ready-to-use-Cardiovascular-Medicine-Norepinephrine-in-Premix-Formulation.
- Norepinephrine Bitartrate in Dextrose Injection. Package insert. Baxter Healthcare; 2021. Accessed September 23, 2021. https://www.baxterpi.com/pi-pdf/Norepinephrine%20Premix%20PI%20CB-30-02-675%20Jan%202021.pdf.
This article originally appeared on MPR